Compare BioNTech SE - ADR (BNTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Yum! Brands, Inc. — how do they compare? BioNTech SE - ADR trades at $90.35 (market cap $22.86B), while Yum! Brands, Inc. trades at $154.26 (market cap $43.60B). The key difference: Yum! Brands, Inc. is the larger of the two by market cap, and Yum! Brands, Inc. pays a 1.9% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | YUM | |
|---|---|---|
Market Cap | $22.86B | $43.60B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $168.16 |
52-Week Low | $83.89 | $138.21 |
Enterprise Value | $6.53B | $54.86B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
YUM Brands trades at $161.69, down 1.13% today, with a bullish technical signal from moving averages and key resistance at $163. The company reported Q1 2026 EPS of $1.50, beating expectations, while revenue grew to $8.21B in 2025. Recent news includes a Taco Bell health investigation and the $2.7B Pizza Hut sale, which may streamline operations.
YUM's outlook is supported by strong cash flow and margin stability, but high debt and competitive pressures pose risks. Analysts maintain a $174.60 price target with a mixed buy/hold consensus. The stock offers growth potential post-Pizza Hut divestiture, though investor sentiment is cautious amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
